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Abstract
The continuous efforts aimed at the identification of new immune epitopes across the MHC system
has led to the discovery that more than one peptide may be restricted to the same HLA antigen
and function as an immune determinant for that association. The aim of this study was to compare
the ability of two overlapping peptides, the nonamer (9-mer) cytomegalovirus (CMV) pp65341–349
(QYDPVAALF) and the decamer (10-mer) CMV pp65341–350 (QYDPVAALFF), and the esadecamer
(16-mer) peptide containing both the 9-mer and 10-mer sequences, CMV pp65340–355
(RQYDPVAALFFFDIDL), to stimulate and maintain over time a T cell immune reactivation by HLA-
A*2402, A*0101, and Cw*0402 cells from CMV-seropositive subjects. The 9-mer, 10-mer, and 16-
mer peptides effectively stimulated CTLs from HLA-A*2402, HLA-A*0101, and HLA-Cw*0402
CMV seropositive donors. This data confirms that both the 9-mer and the 10-mer peptides are
promiscuous and are not restricted to a single HLA antigen. CMV pp65341–349 and CMV pp65341–
350 have the ability to produce CMV-specific CTLs in subjects with several different HLA types,
presenting a practical advantage over other peptides that are restricted only to a single HLA
antigen, and thus being optimal for CMV adoptive immune therapy. Moreover, since the 16-mer
peptide encompasses both the 9-mer and 10-mer peptides, it may be better than either of these
peptides for CMV adoptive immune therapy.
Introduction
In healthy subjects, primary infection with Cytomegalovi-
rus (CMV) is usually mild or asymptomatic and is effec-
tively controlled by the cell-mediated immune response
[1]. However, in immune compromised individuals, such
as those with AIDS or after bone marrow transplantation,
CMV reactivation is associated with significant morbidity
until the individual's immune system is completely recon-
stituted [2]. One method of preventing post-transplant
CMV infection is adoptive immunotherapy using CMV-
specific cytotoxic T cells (CTLs) from the transplant donor
[3]. Several HLA class I restricted peptides derived from
the immune dominant CMV 65 kd matrix phosphopro-
tein (pp65) have been shown to produce CMV-specific
CTLs. Two overlapping HLA-A*2402 restricted peptides
have been described: pp65341–349 and pp65341–350. These
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peptides are a nonamer (9-mer) and a decamer (10-mer)
that overlap except for the last amino acid phenylalanine
(F) at the C-terminus [QYDPVAALF(F)]. Despite their
similarity, the ability of these peptides to induce a T cell
response has been reported to differ [4,5].
Although it has been generally accepted that a unique
CMV peptide is bound and presented by each separate
HLA class I molecule, recent studies suggest that certain
peptides are more promiscuous and may be presented by
more than one HLA class I antigen. In this specific case,
the 9-mer pp65341–349 has been shown to stimulate CTLs
from both HLA-A*2402 and Cw*0402 donors [6], while
the 10-mer pp65341–350 has been shown to be reactive
with both HLA-A*2402 and A*0101 donors [7].
The current investigation sought to compare the potency
of these two peptides and determine the optimum peptide
size for effective CMV adoptive immune therapy. Both
peptides were tested for their ability to stimulate CMV-
specific CTLs in HLA-A*2402, HLA-A*0101, and HLA-
Cw*0402 restriction. In addition, a 16-mer pp65340–355
that includes both the 9-mer and the 10-mer peptides was
tested for its ability to reactivate memory T cells. This spe-
cific 16-mer peptide was selected since it represents the
naturally processed peptide that would encompass both
the 9-mer and 10-mer peptides. IFN-γ  mRNA transcript
production was measured by in vitro cell culture assays in
which the cells were peptide-induced for 3 hours after a 2-
week in vitro sensitization, while IFN-γ  protein release was
measured using in vitro cell culture supernatant collected
at different time points.
The goal of the investigation was to determine whether
both the 9-mer and the 10-mer peptides maintain high
levels of CTL stimulation over time for all HLA restrictions
studied. Moreover, it was important to investigate
whether stimulation with the naturally processed 16-mer
peptide, followed by re-stimulation by the two smaller
peptides embedded within the larger sequence, lead to
effective T cell memory immune response.
Materials and methods
Peptide selection, synthesis and nomenclature
Two overlapping peptides derived from the immune
dominant CMV 65 kd matrix phosphoprotein (pp65), the
nonamer pp65341–349  (QYDPVAALF) and the decamer
pp65341–350 (QYDPVAALFF) peptides were used to ana-
lyze memory T lymphocyte activity in PBMCs collected
from CMV seropositive donors bearing alleles HLA-
A*2402, A*0101, or Cw*0402. The esadecamer pp65340–
355 (RQYDPVAALFFFDIDL) sequence that encompasses
both pp65341–349 (QYDPVAALF) and pp65341–350 (QYD-
PVAALFF) peptides was selected according to its score, as
analyzed by MAPPP (MHC Antigen Peptide Processing
Prediction) [8] based on FRAGPREDICT developed by
Holzhütter [9] (Figure 1). The original sequence of 20
amino acids in length (CMV pp65340–359), as shown in fig-
ure 1, was reduced to 16 amino acids (CMV pp65340–355)
in order to allow the complete reconstitution of this
sequence. The C-terminus of the peptide was reduced to
form a 16-mer sequence and the selection of the 16-mer
did not affect the aim of having both 9-mer and 10-mer
peptides represented in the sequence. The HLA restriction
for this 16 amino acid sequence was not known (Addi-
tional File 1).
The three peptides were synthesized by Princeton Biomol-
ecules (Langhorne, PA) with purity from 90% to 100% as
analyzed by High Performance Liquid Chromatography
(HPLC), dissolved at 100 µg/ml in 50% DMSO and stored
at 4°C. To simplify the peptide nomenclature in this
paper we refer to peptide CMV pp65341–349 (QYDPVAALF)
as the 9-mer peptide, to peptide CMV pp65341–350 (QYD-
PVAALFF) as the 10-mer peptide, and to sequence CMV
pp65340–355  (RQYDPVAALFFFDIDL) as the 16-mer
peptide.
Donor collection and cell preparation
Leukocytes were collected from CMV seropositive donors
bearing alleles HLA-A*2402, A*0101, or Cw*0402 after
obtaining informed consent. The presence of CMV anti-
bodies was analyzed by passive latex agglutination
(CMVSCAN kit, Becton Dickinson Microbiology System,
Cockeysville, MD). MHC class I genotypes were deter-
mined by sequence-specific primer polymerase chain
reaction (PCR). Lymphapheresis was performed using a
CS3000 Plus blood cell separator (Fenwal Divison, Baxter
Health Care, Deerfield, IL), and PBMCs were isolated
from the apheresis product by Ficoll (Pharmacia Biotech,
Wilkstrom, Sweden) density gradient centrifugation.
PBMCs in vitro sensitization
The in vitro sensitization involved a 2-week cell culture in
the presence of peptide and IL-2. Briefly, a 2-week in vitro
sensitization was performed using PBMCs from CMV-
seropositive donors. PBMCs from each donor were plated
at a concentration of 3 × 106 cells/ml in a 24 well/plate
with 2 ml RPMI complete medium (10% AB human
serum, penicillin, gentamycin, glutamine, and 1%
HEPES), and directly stimulated with 3 µg/ml of both test
and control peptides (1 µg/ml peptides for each 106 cells).
Recombinant human interleukin-2 (rhIL-2, 100 U/ml,
PeproTech, Rocky Hill, NJ) was added every other day to
the cell culture. At day 15, each batch of cells was washed
and directly re-stimulated in fresh medium with either test
or control peptide or not re-stimulated. Three hours after
re-stimulation cells were harvested to analyze their IFN-γ
mRNA transcript production by quantitative real time
PCR (qRT-PCR). At three different time points (24, 48,Journal of Translational Medicine 2005, 3:23 http://www.translational-medicine.com/content/3/1/23
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and 72 hours) after re-stimulation supernatants were col-
lected and tested for IFN-γ  protein release following the
ELISA manufacturer's guidelines.
Quantitative real time PCR (qRT-PCR)
IFN-γ  mRNA transcript production by in vitro sensitized
PBMCs was evaluated 3 hours after direct peptide re-
induction, as previously described [5]. Following 2-week
in vitro sensitization (IVS), 2 × 105 PBMCs (final concen-
tration of 1 × 106 cells/ml) were plated in a 96 U-bottom
well/plate with 200 µl of RPMI complete medium, incu-
bated overnight, and then directly stimulated with 1 µg/
ml of specific peptide. After a 3-hour incubation, total
RNA was extracted (RNeasy Mini Kit, Qiagen, Valencia,
CA) and 1 µl of synthesized cDNA (Invitrogen, Carlsbad,
CA) was used as a template to measure IFN-γ  mRNA tran-
Scheme of candidate immune regions within the CMV pp65 as analyzed by MAPP Figure 1
Scheme of candidate immune regions within the CMV pp65 as analyzed by MAPP. The immune dominant CMV 65 
kd matrix phosphoprotein (pp65) is shown above. The highlighted red sequences within the pp65 represent the most immuno-
geneic polypeptides, as predicted by the MAPPP algorithm (threshold ≤  0.5). Their positions in the protein are listed below. 
The two highlighted green peptides, NLVPMVATV and QYDPVAALF(F) are, respectively, the known HLA-A*0201 associated 
pp65495–503 and the two HLA-A*2402 associated overlapping peptides pp65341–349 and pp65341–350. The table refers to each sin-
gle polypeptide's degree of cleavage by proteasome activity at either N-terminus or C-terminus. The number of peptides 
derived from each sequence's proteolitic activity and the corresponding degree of peptide cleavage are also shown. HRC 
(Highest residue cleavage probability); HFC (Highest fragment cleavage probability).
RVSQPSLILVSQYTPDSTPCHR pp65 49-70
VYALPLKM pp65 113-127
LNIPSINVHHYPSAAERKHRHLPV pp65 128-144
FVFPTKDVALRHVVCAHELVCSM pp65 186-208
DVAFTSHEHFGLL pp65 293-305
LLMNGQQIFLEV pp65 319-330
RQYDPVAALFFFDIDLLLQR pp65 340-359
ARNLVPMVATVQGQNLKYQEFFW pp65 493-515
MESRGRRCPEMISVLGPISGHVLKAVFSRGDTPVLPHETRLLQTGIHVRVSQPSLILVSQ
YTPDSTPCHRGDNQLQVQHTYFTGSEVENVSVNVHNPTGRSICPSQEPMSIYVYALPLKM
LNIPSINVHHYPSAAERKHRHLPVADAVIHASGKQMWQARLTVSGLAWTRQQNQWKEPDV
YYTSAFVFPTKDVALRHVVCAHELVCSMENTRATKMQVIGDQYVKVYLESFCEDVPSGKL
FMHVTLGSDVEEDLTMTRNPQPFMRPHERNGFTVLCPKNMIIKPGKISHIMLDVAFTSHE
HFGLLCPKSIPGLSISGNLLMNGQQIFLEVQAIRETVELRQYDPVAALFFFDIDLLLQRG
PQYSEHPTFTSQYRIQGKLEYRHTWDRHDEGAAQGDDDVWTSGSDSDEELVTTERKTPRV
TGGGAMAGASTSAGRKRKSASSATACTSGVMTRGRLKAESTVAPEEDTDEDSDNEIHNPA
VFTWPPWQAGILARNLVPMVATVQGQNLKYQEFFWDANDIYRIFAELEGVWQPAAQPKRR
RHRQDALPGPCIASTPKKHRG
Fragpredict by Holzhütter
PP65 regions thrs = 0.5 MAPPP
SEQUENCE HRC% N-term HRC% C-term Peptides HFC% mean peptide cleavage
pp65 49-70 0.99 0.95 10 0.62508 4>0.6 max 1 6<0.6 min 0.5002
pp65 113-127 0.95 1.00 7 0.8512 5>0.6 max 1 2<0.6 min 0.5003
pp65 128-144 1.00 0.95 6 0.6625 2>0.6 max 1 4<0.6 min 0.5002
pp65 186-208 1.00 0.92 10 0.77493 8>0.6 max 1 2<0.6 min 0.5002
pp65 293-305 0.94 0.84 7 0.80037 5>0.6 max 1 2<0.6 min 0.5004
pp65 319-330 0.96 0.91 5 0.87794 4>0.6 max 1 1<0.6 min 0.5019
pp65 340-359 1.00 0.99 18 0.7538 11>0.6 max 1 7<0.6 min 0.5002
pp65 493-515 0.96 0.82 10 0.77032 6>0.6 max 1 4<0.6 min 0.5000
*HRC and HFC H=1; L=0.5
( MHC Antigen Peptide Processing Prediction)Journal of Translational Medicine 2005, 3:23 http://www.translational-medicine.com/content/3/1/23
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scription by qRT-PCR using an ABI Prism 7900 Sequence
Detection System (Perkin Elmer, Foster City, CA). Quan-
titative real time PCR results were reported as the number
of IFN-γ  gene copies normalized by 105 β -actin gene cop-
ies. All PCR assays were performed in triplicate and
reported as the average. Stimulation index has been
applied based on the negative control values.
ELISA
The release of IFN-γ  protein by in vitro sensitized PBMCs
after peptide re-stimulation was measured using an
enzyme-linked immunosorbent assay (ELISA) kit
(Endogen, Woburn, MA). Supernatants of peptide-stimu-
lated PBMCs were collected at 24, 48, and 72 hours. ELISA
results were extrapolated from a standard curve generated
by linear regression. The assays were performed in dupli-
cate and reported as the average.
Results
IFN-γ  mRNA transcript production by 9-mer, 10-mer, and 
16-mer sensitized PBMCs from HLA-A*2402, A*0101, and 
Cw*0402 donors re-stimulated with their cognate 
determinants
In order to analyze the immediate T cell immune reactiva-
tion to each of the three determinants (9-mer, 10-mer and
16-mer) after 2-week in vitro sensitization, qRT-PCR was
employed to quantitate levels of IFN-γ  mRNA produced
by sensitized cells after a 3-hour peptide-induction. Thus,
following the 2-week peptide (9-mer, 10-mer, and 16-
mer) in vitro sensitization, each batch of sensitized cells
was re-stimulated with the cognate peptides. Although
both 9-mer and 10-mer peptides were able to maintain
high levels of stimulation over this time period for all HLA
restrictions tested, the 9-mer peptide induced the highest
responses in cells expressing HLA-A*2402 (S.I. 4.07–528)
or HLA-Cw*0402 (S.I. 4.15–483) while the 10-mer pep-
tide induced the highest responses in cells expressing
HLA-A*2402 (S.I. 3.5–528) or HLA-A*0101 (S.I. 8.25–
615). The 16-mer peptide was also able to stimulate T cells
from all HLA-A*2402, A*0101 and Cw*0402 donors (S.I.
6.95, 4.96, 5.02) at levels that were approximately equal
to the average of those induced by each single 9-mer and
10-mer induction (Figure 2A).
IFN-γ  mRNA transcript production by 16-mer peptide-
sensitized PBMCs from HLA-A*2402, A*0101, and 
Cw*0402 donors re-stimulated with either the 9-mer or the 
10-mer determinant
In order to analyze the immediate reactivation of memory
T lymphocytes following the 16-mer peptide sensitiza-
tion, the 2-week in vitro 16-mer peptide sensitized cells
were re-stimulated with either 9-mer or 10-mer peptide.
Thus, qRT-PCR was employed to quantitate levels of IFN-
γ  mRNA produced by sensitized cells after a 3-hour pep-
tide-induction. Compared to the previous results, as in
figure 2A, that demonstrated the 9-mer peptide's specifi-
city for HLA-A*2402 and HLA-Cw*0402, the re-stimula-
tion of 2-week in vitro 16-mer peptide sensitized cells with
the 9-mer peptide confirmed the 9-mer peptide's specifi-
city for HLA-A*2402 and HLA-Cw*0402 plus its ability to
enhance the T lymphocytes reactivity in donors bearing
HLA-A*0101 (S.I. 3.96–507). Similarly, the re-stimula-
tion of 2-week in vitro 16-mer peptide sensitized cells with
the 10-mer peptide confirmed this peptide's specificity for
HLA-A*0101 while specifically enhancing the T cell reac-
tivity in HLA-A*2402 donors (S.I. 6.12–236). The HLA-
Cw*0402 specificity was also confirmed and maintained
for the 10-mer peptides (3.58–467), probably adding a
new HLA association to this CMV peptide (Figure 2B).
IFN-γ  protein release by 9-mer, 10-mer, and 16-mer 
peptide-sensitized PBMCs from HLA-A*2402, A*0101, and 
Cw*0402 donors re-stimulated with their cognate 
determinants
Following 2-week in vitro sensitization with 9-mer, 10-
mer or 16-mer peptides of PBMCs from HLA-A*2402,
A*0101, and Cw*0402 donors, supernatants were col-
lected from cell cultures at 24, 48 and 72 hours after the
re-stimulation of each sensitized batch of cells with the
cognate peptides. Despite the fact that both the 9-mer and
10-mer peptides were able to reactivate cells from each of
the three donors at time 0 (Figure 2A), the 9-mer peptide
was weaker than the 10-mer peptide in maintaining a con-
sistent immune T response over time in both the HLA-
A*2402 and HLA-A*0101 donors. In contrast, the 9-mer
peptide was stronger than the 10-mer in stimulating and
maintaining a T immune reactivation and response over
time in donors bearing HLA-Cw*0402. The stimulation
with the 16-mer peptide induced and maintained consist-
ent immune T cell reactivation in all donors tested, as
assessed by levels of IFN-γ  protein production when com-
pared to the positive control (Figure 3).
IFN-γ  protein release by 16-mer sensitized PBMCs from 
HLA-A*2402, A*0101, and Cw*0402 donors re-stimulated 
with either 9-mer or 10-mer determinant
Following 2-week in vitro sensitization of PBMCs from
HLA-A*2402, A*0101, and Cw*0402 donors with the 16-
mer sequence, supernatants were collected from cell cul-
ture at 24, 48 and 72 hours after re-stimulation of 16-mer
peptide-sensitized cells with either 9-mer or 10-mer pep-
tides. It seems that in all donors the re-stimulation of 16-
mer in vitro sensitized cells with the 9-mer and the 10-mer
peptides was able to better induce IFN-γ  protein produc-
tion than 9-mer or 10-mer in vitro sensitized cells that
were stimulated with the cognate peptide either by
enhancing cytokine protein production at each time point
or by better maintaining cytokine protein release over
time. Specifically, this was seen in both HLA-A*2402 and
HLA-A*0101 donors following 9-mer peptide inductionJournal of Translational Medicine 2005, 3:23 http://www.translational-medicine.com/content/3/1/23
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and in the HLA-Cw*0402 donor following 10-mer pep-
tide induction (Figure 4).
Discussion
The adoptive transfer of immunodominant T lym-
phocytes to CMV-infected transplanted patients repre-
sents one of the treatments of choice to clear the CMV
disease and to quickly reconstitute the lost balance
between the CMV infection and the immune system [10-
12]. The use of specific immune peptides to detect and
expand immunocompetent T cells is an important tool
that has been already applied in several clinical trials
[13,14]. Once CMV epitope mapping had been initiated
and led to the identification of epitopes encompassing
several HLA class I antigens, great effots were devoted to
the identification of HLA cross-reactivity of known
immune determinants and the identification of new
determinants. In this specific case, the two overlapping
peptides pp65341–349  (QYDPVAALF) and pp65341–350
(QYDPVAALFF) have been shown to have a marked cross-
IFN-γ  mRNA transcript production by qRT-PCR Figure 2
IFN-γ  mRNA transcript production by qRT-PCR. The ability of the three CMV peptides; pp65341–349, pp65341–350, and 
pp65340–355 to reactivate an immune T lymphocyte response after their cognate re-stimulation of self-induced PBMCs (A) or 
after restimulation with each peptide of 16-mer induced PBMCs (B) was analyzed by qRT-PCR. Levels of IFN-γ  mRNA tran-
script were quantitated after a 3-hour peptide induction. The results were performed in triplicate and reported as the average. 
Levels of IFN-γ  mRNA transcript were normalized by levels of β -actin mRNA transcript and the final values were indicated as 
the ratio over the negative control.
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IFN-γ  protein release by ELISA following re-stimulation of peptide (9-mer, 10-mer, and 16-mer) sensitized PBMCs from all  donors with their cognate determinants Figure 3
IFN-γ  protein release by ELISA following re-stimulation of peptide (9-mer, 10-mer, and 16-mer) sensitized 
PBMCs from all donors with their cognate determinants. Supernatants of peptide (9-mer pp65341–349, 10-mer pp65341–
350, and 16-mer pp65340–355) sensitized PBMCs from CMV seropositive donors HLA-A*2402, A*0101, and Cw*0402 were col-
lected at three time point of 24, 48, and 72 hours after cell re-stimulation with each cognate peptide: 9-mer (blue segment), 10-
mer (purple segment), and 16-mer (orange segment). The figure shows the peptide induction and the maintenance over time of 
T lymphocyte reactivation after cognate peptide recall compared to the positive control (green segment) for each individual 
HLA association: HLA-A24 (top), HLA-A1 (middle), HLA-Cw4 (bottom).
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IFN-γ  protein release ELISA following re-stimulated of 16-mer sensitized PBMCs from all donors with either the 9-mer or 10- mer determinant Figure 4
IFN-γ  protein release ELISA following re-stimulated of 16-mer sensitized PBMCs from all donors with either 
the 9-mer or 10-mer determinant. Supernatants of 16-mer pp65340–355-sensitized PBMCs from CMV seropositive donors 
HLA-A*2402, A*0101, and Cw*0402 were collected at the three time points of 24 hours (black), 48 hours (orange), and 72 
hours (yellow) after cell re-stimulation with either the 9-mer pp65341–349 or 10-mer pp65341–350 peptide. The figure shows the 
peptide induction and maintenance over time of the T lymphocyte reactivation from 16-mer pp65340–355-sensitized PBMCs 
after either 9-mer pp65 341–349 (9/16) or 10-mer pp65 341–350 (10/16) peptide recall compared to the specific 16-mer pp65340–355 
re-induction (16) for each individual HLA association: HLA-A24 (top), HLA-A1 (middle), HLA-Cw4 (bottom).
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reactivity. First, it was shown that pp65341–349 is restricted
to HLA-A*2402 and Cw*0402 and pp65341–350 to HLA-
A*2402 and A*0101 [6,7]. In this study a new HLA specif-
icity for the 9-mer to HLA-A*0101 and for the 10-mer to
HLA-Cw*0402 is well described. Furthermore, this study
showed that both peptides were able to effectively stimu-
late immune T cell responses from HLA-A*2402, A*0101
and Cw*0402 donors, confirming that these peptides are
promiscuous and not restricted to a single HLA type.
While both the 9-mer and 10-mer peptides are able to
maintain high levels of stimulation over time in HLA-
A*2402 donors, both are also able to induce and main-
tain an immune reactivation in donors bearing their other
noted HLA associations. In fact, the 9-mer is better able to
maintain stimulation in HLA-Cw*0402 donors and the
10-mer is better able to do so in HLA-A*0101 donors.
Interestingly, another new finding emerged: both the 9-
mer and 10-mer peptides were able to induce a popula-
tion of restricted T lymphocytes from a cell population
that had been in vitro sensitized with a peptide sequence
that encompassed the two peptides. The 16-mer peptide is
able to effectively stimulate T cells from HLA-A*2402,
A*0101 and Cw*0402 at levels that are well maintained
over time. In particular, it seems that the 9-mer and 10-
mer peptide reactivation of cells previously sensitized
with the 16-mer peptide results in enhanced T cell reacti-
vation in all donors. Although these results need to be
confirmed and validated by further in vivo studies, we
speculate that the use of this 16-mer region rather than the
single 9-mer or 10-mer peptides would be advantageous
in clinical modalities such as adoptive transfer of epitope-
specific T lymphocytes or epitope-specific vaccinations.
These results support the potential use of the 16-mer pep-
tide in CMV adoptive immune therapy [15].
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